切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2022, Vol. 16 ›› Issue (10) : 975 -981. doi: 10.3877/cma.j.issn.1674-0785.2022.10.010

所属专题: 乳腺疾病

临床研究

乳腺癌同时合并原发性肺癌患者临床病理特征及预后影响因素
杨珊1, 高威1, 程萌1, 史佳杰1, 耿翠芝1, 李赛男1,()   
  1. 1. 050011 石家庄,河北医科大学第四医院乳腺中心
  • 收稿日期:2022-08-14 出版日期:2022-10-15
  • 通信作者: 李赛男
  • 基金资助:
    河北省卫生厅课题(20210016)

Clinicopathological features and prognostic factors of patients with breast cancer combined with primary lung cancer

Shan Yang1, Wei Gao1, Meng Cheng1, Jiajie Shi1, Cuizhi Geng1, Sainan Li1,()   

  1. 1. Breast Disease Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
  • Received:2022-08-14 Published:2022-10-15
  • Corresponding author: Sainan Li
引用本文:

杨珊, 高威, 程萌, 史佳杰, 耿翠芝, 李赛男. 乳腺癌同时合并原发性肺癌患者临床病理特征及预后影响因素[J/OL]. 中华临床医师杂志(电子版), 2022, 16(10): 975-981.

Shan Yang, Wei Gao, Meng Cheng, Jiajie Shi, Cuizhi Geng, Sainan Li. Clinicopathological features and prognostic factors of patients with breast cancer combined with primary lung cancer[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(10): 975-981.

目的

探究乳腺癌合并原发性肺癌患者的临床病理特征和预后,为乳腺癌同时合并原发性肺癌患者的诊断及鉴别诊断提供帮助。

方法

回顾性分析了2009年9月至2021年1月于河北医科大学第四医院行进行治疗的乳腺癌患者临床病理资料(双原发组及乳腺癌组),并进行差异分析。使用Kaplan-Meier方法绘制生存曲线,并应用单多因素Logistic回归分析探究乳腺癌患者发生肺癌的危险或保护因素。使用单多因素Cox回归分析探究影响患者总生存期的危险或保护因素。

结果

使用倾向匹配得分(PSM)方法对2组患者进行匹配,纳入双原发组患者40例,乳腺癌组患者100例。差异分析表明,2组患者在雌激素受体(ER)表达、孕激素受体(PR)表达、人表皮生长因子受体-2(HER2)表达、Ki67表达方面具有统计学差异(P<0.05)。单多因素Logistic回归分析表明,PR表达阴性、HER2表达阴性、Ki67低表达是乳腺癌患者发生肺癌的独立危险因素(P<0.05)。生存曲线表明,双原发组患者的总生存期短于乳腺癌组。多因素Cox分析则表明,肿瘤分级是影响患者总生存期的独立保护因素(P<0.05)。

结论

PR阴性、HER2阴性、Ki67低表达的患者,伴发原发性肺癌的概率更高。N分期、M分期、肿瘤分期、肿瘤分级、ER表达阴性是影响这些患者总生存期的危险因素。上述因素可能在乳腺癌、肺癌双原发癌中具有重要作用。

Objective

To explore the clinicopathological features and prognosis of breast cancer patients with primary lung cancer, in order to provide help for the diagnosis and differential diagnosis of such patients.

Methods

The clinicopathological data of breast cancer patients with or without primary lung cancer (double primary cancer group and breast cancer group) treated at the Fourth Hospital of Hebei Medical University from September 2009 to January 2021 were retrospectively analyzed, and differences were analyzed. Survival curves were drawn using the Kaplan-Meier method, and single-multivariate logistic regression analysis was used to explore the risk or protective factors for lung cancer in breast cancer patients. Single and multivariate Cox regression analyses were used to explore the risk or protective factors affecting the overall survival of patients.

Results

The two groups of patients were matched using the propensity score matching method, including 40 patients in the double primary cancer group and 100 patients in the breast cancer group. There were significant differences in estrogen receptor (ER) expression, progesterone receptor (PR) expression, human epidermal growth factor receptor 2 (HER2) expression, and Ki67 expression between the two groups (P<0.05). Single multivariate Logistic regression analysis showed that PR negativity, HER2 negativity, and low Ki67 expression were independent risk factors for lung cancer in breast cancer patients (P<0.05). Survival curve analysis demonstrated that the overall survival of patients in the double primary cancer group was shorter than that of the breast cancer group. Multivariate Cox analysis demonstrated that tumor grade was an independent protective factor for the overall survival of patients (P<0.05).

Conclusion

Breast cancer patients with PR-negative, HER2-negative, and low Ki67 expression have a higher probability of developing primary lung cancer. N stage, M stage, tumor stage, tumor grade, and ER negativity are risk factors affecting the overall survival of these patients. The above factors may play an important role in the dual primary breast cancer and lung cancer.

表1 乳腺癌和肺癌患者与单独乳腺癌患者的临床病理学特征[例(%)]
表2 双发癌的单因素和多因素Logistic回归分析
图1 双原发组及乳腺癌组患者的生存曲线
表3 双发癌的单因素和多因素Cox回归分析
1
Lee J, Park S, Kim S, et al. Characteristics and survival of breast cancer patients with multiple synchronous or metachronous primary cancers [J]. Yonsei Med J, 2015, 56(5): 1213-1220.
2
Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program [J]. Oncologist, 2007, 12(1): 20-37.
3
Mariotto AB, Rowland JH, Ries LA, et al. Multiple cancer prevalence: a growing challenge in long-term survivorship [J]. Cancer Epidemiol Biomarkers Prev, 2007, 16(3): 566-571.
4
Lee KD, Chen SC, Chan CH, et al. Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan [J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(10): 2647-2655.
5
Bao S, Jiang M, Wang X, et al. Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population-based study[J]. Cancer Med, 2021, 10(23):8662-8672.
6
Kerendi F, Gal A, Corvera JS, et al. Characteristics of second primary lung malignancy in patients with known breast cancer[J]. South Med J, 2009, 102(3):269-274.
7
Schonfeld SJ, Curtis RE, Anderson WF, et al. The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status[J]. Cancer Causes Control, 2012, 23(10):1721-1728.
8
贺科文, 魏巍, 刘兆芸,等. 乳腺癌合并原发性肺癌与乳腺癌肺转移患者的临床病理特征分析[J]. 中华肿瘤杂志, 2018, 40(3): 201-205.
9
Copur MS, Manapuram S. Multiple primary tumors over a lifetime [J]. Oncology (Williston Park), 2019, 33(7): 629384.
10
Molina-Montes E, Requena M, Sánchez-Cantalejo E, et al. Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis [J]. Gynecol Oncol, 2015, 136(1): 158-171.
11
Wei JL, Jiang YZ, Shao ZM. Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study [J]. Int J Clin Oncol, 2019, 24(8): 934-940.
12
Sung H, Freedman RA, Siegel RL, et al. Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status [J]. Cancer, 2021, 127(18): 3310-3324.
13
Lee KD, Chen SC, Chan CH, et al. Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan [J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(10): 2647-2655.
14
Bao S, Jiang M, Wang X, et al. Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population-based study [J]. Cancer Med, 2021, 10(23): 8662-8672.
15
Wang R, Yin Z, Liu L, et al. Second primary lung cancer after breast cancer: A population-based study of 6,269 women [J]. Front Oncol, 2018, 8: 427.
16
Wang Y, Li J, Chang S, et al. Risk and influencing factors for subsequent primary lung cancer after treatment of breast cancer: A systematic review and two meta-analyses based on four million cases [J]. J Thorac Oncol, 2021, 16(11): 1893-1908.
17
Hu Z, Zou X, Qin S, et al. Hormone receptor expression correlates with EGFR gene mutation in lung cancer in patients with simultaneous primary breast cancer [J]. Transl Lung Cancer Res, 2020, 9(2): 325-336.
18
Liu J, Hu Z, Feng Y, et al. Problems to affect long-term survival for breast cancer patients: An observational study of subsequent lung/bronchus malignancies [J]. Medicine (Baltimore), 2018, 97(39): e12603.
19
Ishibashi H, Suzuki T, Suzuki S, et al. Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy [J]. Cancer Res, 2005, 65(14): 6450-6458.
20
Lin EP, Lin CH, Yang CY, et al. Population-based cohort study reveals distinct associations between female lung cancer and breast cancer in Taiwan [J]. JCO Clin Cancer Inform, 2018, 2: 1-14.
21
Lin X, Lin X, Li Y, et al. Differential second primary malignancy occurrence after breast cancer according to HER2 status: A population-based study [J]. Int J Gen Med, 2021, 14: 8775-8784.
22
Liu JZ, Zhang WF, Ren XF, et al. Clinicopathological characteristics and prognosis of breast cancer patients with lung cancer: A study based on 19,807 breast cancer patients [J]. Neoplasma, 2022, 69(2): 484-490.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[3] 杨柳, 宋振川, 王新乐. 乳腺癌改良根治术联合背阔肌复位的临床疗效评估[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 269-273.
[4] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[5] 宋佳, 汪波, 孙凯律, 商江峰, 吴旦平, 肇毅. 吲哚菁绿荧光显影联合亚甲蓝染色在乳腺癌前哨淋巴结活检中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 498-501.
[6] 孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[7] 唐丹萍, 王萍, 江孟蝶, 杨晓蓉. 自体脂肪移植在乳腺癌术后乳房重建的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 582-585.
[8] 袁延丽, 屈卓军, 崔会慧, 王菁, 高贝贝, 潘院. 原发性肺癌切除术后谵妄的危险因素及预后分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 701-706.
[9] 刘一鸣, 温佳新, 赵恺, 薛志强. ⅢA 期肺腺癌新辅助治疗后胸腔镜右肺中下叶切除术[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 311-313.
[10] 黄程鑫, 陈莉, 刘伊楚, 王水良, 赖晓凤. OPA1 在乳腺癌组织的表达特征及在ER阳性乳腺癌细胞中的生物学功能研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 275-284.
[11] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[12] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[13] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
阅读次数
全文


摘要